Reason for request
Indication extension
Summary of opinion
Favourable opinion for reimbursement in the following indication: “KEYTRUDA, in combination with chemoradiotherapy (external beam radiation therapy followed by brachytherapy), in the treatment of FIGO 2014 Stage III (extension onto the pelvic wall or lower one-third of the vagina and/or causing hydronephrosis or non-functioning kidney) to IVA (involvement of the mucosa of bladder/rectum -adjacent pelvic organ spread-) with or without involvement of the pelvic and/or para-aortic lymph nodes) locally advanced cervical cancer in adults who have not received prior definitive therapy.”
Clinical Benefit
| Substantial |
The Committee deems that the clinical benefit of KEYTRUDA (pembrolizumab), in combination with chemoradiotherapy (external beam radiation therapy followed by brachytherapy), is substantial in the indication: “in combination with chemoradiotherapy (external beam radiation therapy followed by brachytherapy), in the treatment of FIGO 2014 Stage III (extension onto the pelvic wall or lower one-third of the vagina and/or causing hydronephrosis or non-functioning kidney) to IVA (involvement of the mucosa of bladder/rectum -adjacent pelvic organ spread-) with or without involvement of the pelvic and/or para-aortic lymph nodes) locally advanced cervical cancer in adults who have not received prior definitive therapy.”
|
Clinical Added Value
| moderate |
Considering:
- demonstration in a randomised, double-blind, phase 3 study (KN-A18 trial, including 56.7% FIGO 2014 stage III - IVA patients) of the superiority of pembrolizumab compared to chemoradiotherapy, for the treatment of FIGO stage IB2-IIB and III - IVA locally advanced cervical cancer in adults who have not received prior definitive therapy, in terms of:
- progression-free survival with an HR = 0.70 (95% CI = [0.55; 0.89]; p = 0.002 < the predefined threshold of 0.0172), 7% patients progressed or died in the experimental group versus 29.0% patients in the control group. The median PFS was not reached in either of the two groups.
- overall survival with an HR = 0.67 (95% CI = [0.50; 0.90]; p = 0.0040 < 0.01026), 2% deaths in the experimental group versus 20.5% patients in the control group. The median OS was not reached in either of the two groups.
And despite:
- the absence of any formal conclusion that can be drawn based on the quality of life findings;
- a safety profile deemed to be acceptable compared to chemoradiotherapy but marked by an excess toxicity with grade ≥ 3 AEs reported in 78.3% of patients in the pembrolizumab group and 70.0% of patients in the placebo group). In addition, 20.6% of patients in the pembrolizumab group and 14.9% of patients in the placebo group had an AE resulting in definitive discontinuation of pembrolizumab treatment.
The Committee deems that KEYTRUDA (pembrolizumab) 25 mg/ml, concentrate for solution for infusion, in combination with chemoradiotherapy (external beam radiation therapy followed by brachytherapy), provides a moderate clinical added value (CAV III) compared to chemoradiotherapy.
|
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
S2xJap85C9pvVMmR